Tandem Diabetes Care upgraded by Piper Sandler with a new price target
$TNDM
Medical/Dental Instruments
Health Care
Piper Sandler upgraded Tandem Diabetes Care from Neutral to Overweight and set a new price target of $33.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2026 | $15.50 | Hold | Deutsche Bank |
| 6/1/2026 | $27.00 | Equal Weight → Overweight | Wells Fargo |
| 5/12/2026 | Hold | The Benchmark Company | |
| 3/19/2026 | $35.00 | Hold → Buy | Truist |
| 3/17/2026 | $33.00 | Neutral → Overweight | Piper Sandler |
| 2/23/2026 | $50.00 | Hold → Buy | Lake Street |
| 2/20/2026 | $30.00 | Underperform → Neutral | BofA Securities |
| 1/27/2026 | $25.00 | Buy | TD Cowen |
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2™ insulin pump with Control-IQ+TM automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor in five countries. This launch expands continuous glucose monitoring choice for t:slim X2 pump users in the United Kingdom, Switzerland, Sweden, Finland, and Italy. Tandem expects to add additional countries in 2026, including Belgium, the Netherlands, and Germany."People using AID want fle
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery (AID) systems in Europe. The t:slim X2 and Tandem Mobi insulin delivery systems running Control-IQ+ AID technology are now approved for use by people with type 1 diabetes during pregnancy and adults with type 2 diabetes. "These expanded indications underscore the strength of our portfolio and our commitment to bringing innovative diabetes technology to more people worldwide," said John Sheridan, president and chief executive officer. "By expanding access to our AID technology, we're broadening ou
SD - TANDEM DIABETES CARE INC (0001438133) (Filer)
S-8 - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
Deutsche Bank initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $15.50
Wells Fargo upgraded Tandem Diabetes Care from Equal Weight to Overweight and set a new price target of $27.00
The Benchmark Company initiated coverage of Tandem Diabetes Care with a rating of Hold
For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy
For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins the board as an independent director and will serve on the board's Audit Committee and Cybersecurity and Data Oversight Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112460451/en/Sandra Beaver joins Tandem Diabetes Care Board of Directors. "We welcome Sandra to our Board of Directors at this pivotal stage in Tandem's evolution," said John Sheridan, president and CEO. "Sandra is a dynamic finance
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026. First Quarter 2026 Financial and Strategic Highlights Achieved record first quarter pump shipments, sales and gross margin: Shipments of more than 29,000 pumps worldwide, including 19,000 pumps in the United States Sales of $247.2 million worldwide, including $160.8 million in the United States Gross margin of 55%, up 480 basis points compared to first quarter 2025 Launched pay-as-you-go reimbursement model in the United States
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI870b